Learn More
BACKGROUND Many patients with aggressive B-cell lymphomas and high clinical risk score still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized that intensified(More)
e18519 Background: In a phase II study for patients with DLBCL aged 18-65 and high-risk disease (aaIPI 2-3), we evaluated end-therapy FDG PET analysis performed at five of the centres and a score(More)